Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05657834 | Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects | PHASE1 | COMPLETED | 8 | — | — | Nov 21, 2022 | Dec 21, 2022 | Dec 28, 2022 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1 | EXPERIMENTAL | Single dose of TVB-2640, 50 mg, oral administration |
| Name | Type | Description |
|---|---|---|
| [14C]-TVB-2640 | DRUG | 50 mg of TVB-2640 oral administration |
Key Inclusion Criteria: * Males, of any race, between 19 and 55 years of age, inclusive. * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic ...